Samsung Electronics Takes Step Into Korea's Biosimilar Foray With IND For MabThera Generic
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's electronics and semiconductor giant Samsung Electronics has submitted an investigational new drug application to Korea FDA to conduct clinical trials for its biosimilar of Roche's MabThera.
You may also be interested in...
Korea FDA OKs Samsung's Clinical Trial Application For Roche's MabThera Biosimilar
SEOUL - Korea FDA approved March 8 Samsung Electronics' investigational new drug application to commence Phase I clinical trials of a biosimilar of Roche's MabThera, marking the first step of the electronics and semiconductor giant's ambition to enter the healthcare sector
Korea FDA OKs Samsung's Clinical Trial Application For Roche's MabThera Biosimilar
SEOUL - Korea FDA approved March 8 Samsung Electronics' investigational new drug application to commence Phase I clinical trials of a biosimilar of Roche's MabThera, marking the first step of the electronics and semiconductor giant's ambition to enter the healthcare sector
Samsung Looks To Mirror Fellow Korean Pharma Celltrion's Path From CMO To Biosimilars Developer With Quintiles JV
Samsung plans to begin construction on its manufacturing plant in Incheon during the first half of this year, and production is expected to commence in the first half of 2013.